PMID- 32553554
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220531
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 146
DP  - 2020 Aug
TI  - Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung 
      adenocarcinoma.
PG  - 366-369
LID - S0169-5002(20)30427-X [pii]
LID - 10.1016/j.lungcan.2020.05.008 [doi]
AB  - OBJECTIVE: Immune checkpoint inhibitors (ICI) have become a major treatment in 
      advanced non small cell lung cancer (NSCLC). However, some patients do not 
      benefit from ICI, especially those harboring an ALK rearrangement. Here, we 
      report a case of prolonged complete tumor response to immunotherapy in an 
      ALK-rearranged NSCLC patient. MATERIALS AND METHODS: We verify ALK expression and 
      rearrangement on formalin-fixed paraffin-embedded tumor samples of the patient by 
      Immunohistochemistry and Fluorescence In Situ Hybridization analysis. The patient 
      provided written informed consent authorizing publication of clinical case. 
      RESULTS: We report the case of 48 years old man with a ALK-rearranged NSCLC. This 
      patient displayed a complete response for 16 months under nivolumab therapy in 
      third line setting after ceritinib and platin based chemotherapy. CONCLUSION: 
      This is the first case of complete and prolonged response to ICI in ALK 
      rearranged NSCLC. This case supports the idea that some ALK rearranged NSCLC 
      could durably benefit from immunotherapy.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Baldacci, Simon
AU  - Baldacci S
AD  - Univ Lille, Department of Thoracic Oncology, CHU Lille, F-59000, Lille, France.
FAU - Gregoire, Valerie
AU  - Gregoire V
AD  - Univ Lille, Department of Pathology, CHU Lille, F-59000, Lille, France.
FAU - Patrucco, Enrico
AU  - Patrucco E
AD  - Department of Molecular Biotechnology and Health Sciences, University of Torino, 
      Italy.
FAU - Chiarle, Roberto
AU  - Chiarle R
AD  - Department of Molecular Biotechnology and Health Sciences, University of Torino, 
      Italy; Department of Pathology, Boston Children Hospital and Harvard Medical 
      School, Boston, USA.
FAU - Jamme, Philippe
AU  - Jamme P
AD  - Univ Lille, Department of Thoracic Oncology, CHU Lille, F-59000, Lille, France.
FAU - Wasielewski, Eric
AU  - Wasielewski E
AD  - Univ Lille, Department of Thoracic Oncology, CHU Lille, F-59000, Lille, France.
FAU - Descarpentries, Clotilde
AU  - Descarpentries C
AD  - Univ Lille, Department of Molecular Oncology, CHU Lille, F-59000, Lille, France.
FAU - Copin, Marie-Christine
AU  - Copin MC
AD  - Univ Lille, Department of Pathology, CHU Lille, F-59000, Lille, France.
FAU - Awad, Mark M
AU  - Awad MM
AD  - Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical 
      School, Boston, MA, USA.
FAU - Cortot, Alexis B
AU  - Cortot AB
AD  - Univ Lille, Department of Thoracic Oncology, CHU Lille, F-59000, Lille, France. 
      Electronic address: alexis.cortot@chru-lille.fr.
LA  - eng
PT  - Case Reports
DEP - 20200527
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - *Adenocarcinoma of Lung/diagnosis/drug therapy/genetics
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors
MH  - Receptor Protein-Tyrosine Kinases/genetics
OTO - NOTNLM
OT  - ALK rearrangement
OT  - Immunotherapy
OT  - Non small cell lung cancer
OT  - Tyrosine kinase inhibitor
EDAT- 2020/06/20 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/07 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - S0169-5002(20)30427-X [pii]
AID - 10.1016/j.lungcan.2020.05.008 [doi]
PST - ppublish
SO  - Lung Cancer. 2020 Aug;146:366-369. doi: 10.1016/j.lungcan.2020.05.008. Epub 2020 
      May 27.